Foghorn Therapeutics
FHTX
69 hedge funds and large institutions have $177M invested in Foghorn Therapeutics in 2024 Q1 according to their latest regulatory filings, with 12 funds opening new positions, 18 increasing their positions, 18 reducing their positions, and 2 closing their positions.
500% more first-time investments, than exits
New positions opened: 12 | Existing positions closed: 2
410% more call options, than puts
Call options by funds: $51K | Put options by funds: $10K
17% more funds holding
Funds holding: 59 → 69 (+10)
5% more capital invested
Capital invested by funds: $170M → $177M (+$7.81M)
0% more funds holding in top 10
Funds holding in top 10: 2 → 2 (0)
0% more repeat investments, than reductions
Existing positions increased: 18 | Existing positions reduced: 18
0.13% less ownership
Funds ownership: 62.29% → 62.16% (-0.13%)
Top Buyers
Top Sellers
FHTX Hedge Fund Activity: Q1 2024 in Review
69 of the 6,942 institutional investors tracked by Wall St. Rank reported a position in Foghorn Therapeutics (FHTX) for Q1 2024, worth a combined $177M — up 4.6% from $170M a quarter earlier.
Buyers outnumbered sellers: 12 funds opened new FHTX positions and 2 closed out — a net gain of 10 holders — while 18 added to existing stakes and 18 trimmed.
The largest buyer was Raymond James & Associates, adding an estimated $900K. The largest seller was Morgan Stanley, cutting an estimated $751K.
- 69 institutional investors held Foghorn Therapeutics (FHTX) as of Q1 2024, up from 59 in Q4 2023.
- Funds reported $177M of Foghorn Therapeutics stock for Q1 2024, up 4.6% quarter-over-quarter.
- 12 funds opened new Foghorn Therapeutics positions in Q1 2024 and 2 closed out, a net change of +10 holders.
- The largest Foghorn Therapeutics buyer in Q1 2024 was Raymond James & Associates, an estimated $900K added.
- The largest Foghorn Therapeutics seller in Q1 2024 was Morgan Stanley, an estimated $751K sold.
Based on aggregated 13F filings for Q1 2024.